Jun 16
2020
Phanes Therapeutics reveals a new bispecific antibody technology platform at BIO Digital 2020
SAN DIEGO, June 16, 2020 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology...
Read More
Dec 12
2019
PHANES THERAPEUTICS TO PRESENT AT BIOTECH SHOWCASE™ 2020 IN SAN FRANCISCO
Company will showcase its bispecific antibody platform PACbody™ and immuno-oncology pipeline San Diego, California/December 12, 2019 – Phanes Therapeutics, Inc.,...
Read More
Nov 7
2019
PHANES AND FOSUN KITE FORM STRATEGIC ALLIANCE FOR INNOVATIVE CAR-T PRODUCTS TO TREAT SOLID TUMORS
Phanes Therapeutics and Phanes Biopharmaceuticals (“Phanes”) recently formed an important strategic alliance with Fosun Kite Biotechnology (“Fosun Kite”). Under the...
Read More
Sep 17
2019
PHANES AND HANMI ANNOUNCE LICENSING AGREEMENT TO DEVELOP BI- AND/OR MULTI-SPECIFIC ANTIBODIES
Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has signed a...
Read More
Jul 24
2019
MERCK TO PROVIDE BIORELIANCE® END-TO-END SOLUTIONS TO PHANES THERAPEUTICS
Collaboration to accelerate development and manufacturing of Bispecific Antibody Merck plans to offer Phanes a full suite of products and...
Read More
Mar 13
2018
CROWNBIO ENTERS STRATEGIC PARTNERSHIP WITH PHANES THERAPEUTICS TO ACCELERATE DISCOVERY AND DEVELOPMENT OF PHANES’ NOVEL ONCOLOGY AGENTS
Original link: https://blog.crownbio.com/press/partnership-with-phanes (San Diego, Calif., March 13, 2018) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:...
Read More
Dec 14
2017
WUXI BIOLOGICS AND PHANES ANNOUNCE STRATEGIC PARTNERSHIP
Shanghai and San Diego, Dec. 14, 2017 — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering...
Read More
